(RTTNews) - Teoxane SA Monday revealed a proposal to acquire Revance Therapeutics, Inc. (RVNC) for $3.60 per share in cash. The Geneva, Switzerland-based medical aesthetics sector company said it currently owns 6.2 percent stake in Revance.
RVNC is currently up 16.02 percent at $3.58 on a volume of 4,461,212.
The offer provides a 16 percent premium over the $3.10 per share price in Revance's amended and restated merger agreement with Crown Laboratories, Inc., as on December 9, 2024.
Teoxane said it is already in discussions with financing sources to secure committed financing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
